"Sleep disorder drugs (hypnotic and sedative drugs) overview
Insomnia, a disorder in which there is difficulty sleeping, occurs occasionally in most people but usually lasts only a few days. The body then "corrects" itself "...
(Generic versions may still be available.)
- Patient Information:
Details with Side Effects
Permax (pergolide mesylate) is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson†s disease.
Evidence to support the efficacy of pergolide mesylate as an antiparkinsonian adjunct was obtained in a multicenter study enrolling 376 patients with mild to moderate Parkinson†s disease who were intolerant to l-dopa/carbidopa as manifested by moderate to severe dyskinesia and/or on-off phenomena. On average, the patients evaluated had been on l-dopa/carbidopa for 3.9 years (range, 2 days to 16.8 years). The administration of pergolide mesylate permitted a 5% to 30% reduction in the daily dose of l/dopa. On average, these patients treated with pergolide mesylate maintained an equivalent or better clinical status than they exhibited at baseline.
DOSAGE AND ADMINISTRATION
Administration of Permax (pergolide mesylate) should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
Permax (pergolide mesylate) is usually administered in divided doses 3 times per day. During dosage titration, the dosage of concurrent l-dopa/carbidopa may be cautiously decreased.
In clinical-studies, the mean therapeutic daily dosage of Permax (pergolide mesylate) was 3 mg/day. The average concurrent daily dosage of l-dopa/carbidopa (expressed as l-dopa) was approximately 650 mg/day. The efficacy of Permax (pergolide mesylate) at doses above 5 mg/day has not been systematically evaluated.
- 0.05 mg, ivory, debossed with A615, (UC5336)-(RxPak* of 30) NDC 59075-615-30
- 0.25 mg, green, debossed with A625, (UC5337)-(RxPak of 100) NDC 59075-625-10
- 1 mg, pink, debossed with A630, (UC5338)--(RxPak of 100) NDC 59075-630-10
*All RxPaks (prescription packages, Lilly) have safety closures.
Store at controlled room temperature, 59 to 86° F (15 to 30° C ).
CAUTION-Federal (USA) law prohibits dispensing without prescription.
Updated Apr 08, 2003
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Permax Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.